High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison

被引:120
作者
Tanaka, M
Ino, Y
Nakagawa, K
Tago, M
Todo, T
机构
[1] Univ Tokyo, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Dept Neurooncol & Mol Therapeut, Tokyo, Japan
[3] Univ Tokyo, Dept Radiat Oncol, Tokyo, Japan
关键词
D O I
10.1016/S1470-2045(05)70395-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background Although radiotherapy remains the main postoperative treatment for patients with malignant glioma, modifications to regimens have not improved the poor outlook of patients with this disease. We aimed to investigate whether high-dose conformal radiotherapy improves the survival of patients with supratentorial malignant glioma. compared with conventional radiotherapy. Methods 29 patients with anaplastic astrocytoma. and 61 patients with glioblastoma who received high-dose conformal radiotherapy during 1990-2002 were compared with 34 patients with anaplastic astrocytoma and 60 patients with glioblastoma who received conventional 60 Gy radiotherapy during 1979-89. 77 of the 90 patients receiving high-dose radiotherapy were given 80 Gy; the remaining 13 patients, all with glioblastoma, received 90 Gy. Radiotherapy was planned on the basis of images taken before surgery, and doses were delivered in 2 Gy per fraction per day for 5 days a week. Hazard ratios for death were calculated with a Cox model, and were adjusted for age, Karnofsky performance scale, tumour size, and extent of resection. Findings Patients who received high-dose radiotherapy had significantly longer overall survival compared with those who received conventional radiotherapy (adjusted hazard ratio 0.30 [95% CI 0.12-0.6], p=0.011 for anaplastic astrocytoma and 0.49 [0.8-0.87], p=0.014 for glioblastoma). Patients with anaplastic astrocytoma. in the high-dose group have not yet reached median survival; median survival in the conventional radiotherapy group was 22. months (95% CI 20.6-24.0). 5-year survival was 51.3% (29.2-73.4) for the high-dose group and 14.7% (0-0-30-0) for the conventional group. Median survival inpatients with glioblastoma was 16.2months (12.8-19-6) for the high-dose group and 12.4 months (10.0-14.8) for the conventional group. 2-year survival was 38.4% (23.5-53.3) for the high-dose group and 11.4% (0.0-25.3) for the conventional group. Survival did not differ between those that received 80 Gy radiotherapy and those that received 90 Gy (hazard ratio 0.94 [95% Cl 0.42-2.12]). The higher frequency of radiation-induced white matter abnormality in the high-dose group compared with the conventional radiotherapy group did not lead to increased disability. Interpretation High-dose, standard-fractionated radiotherapy shows potential as the main postoperative treatment for patients with supratentorial malignant glioma.
引用
收藏
页码:953 / 960
页数:8
相关论文
共 42 条
[1]
Aoki Y, 1987, Radiat Med, V5, P131
[2]
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme [J].
Athanassiou, H ;
Synodinou, M ;
Maragoudakis, E ;
Paraskevaidis, M ;
Verigos, C ;
Misailidou, D ;
Antonadou, D ;
Saris, G ;
Beroukas, K ;
Karageorgis, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2372-2377
[3]
A MEDICAL-RESEARCH-COUNCIL TRIAL OF 2 RADIOTHERAPY DOSES IN THE TREATMENT OF GRADE-3 AND GRADE-4 ASTROCYTOMA [J].
BLEEHEN, NM ;
STENNING, SP .
BRITISH JOURNAL OF CANCER, 1991, 64 (04) :769-774
[4]
The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data [J].
Chakravarti, A ;
Dicker, A ;
Mehta, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03) :927-931
[5]
Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy [J].
Chan, JL ;
Lee, SW ;
Fraass, BA ;
Normolle, DP ;
Greenberg, HS ;
Junck, LR ;
Gebarski, SS ;
Sandler, HM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1635-1642
[6]
CORN BW, 1994, CANCER, V74, P2828, DOI 10.1002/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO
[7]
2-K
[8]
Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 gy) based on tumor volume (&gt; 20 or ≤ 20 CM2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients [J].
Coughlin, C ;
Scott, C ;
Langer, C ;
Coia, L ;
Curran, W ;
Rubin, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (05) :1351-1358
[9]
TOLERANCE OF NORMAL TISSUE TO THERAPEUTIC IRRADIATION [J].
EMAMI, B ;
LYMAN, J ;
BROWN, A ;
COIA, L ;
GOITEIN, M ;
MUNZENRIDER, JE ;
SHANK, B ;
SOLIN, LJ ;
WESSON, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01) :109-122
[10]
Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme [J].
Floyd, NS ;
Woo, SY ;
Teh, BS ;
Prado, C ;
Mai, WY ;
Trask, T ;
Gildenberg, PL ;
Holoye, P ;
Augspurger, ME ;
Carpenter, LS ;
Lu, HH ;
Chiu, JK ;
Grant, WH ;
Butler, EB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03) :721-726